5‐HT3 Receptors


The 5‐HT3 receptor is a cation‐selective member of the pentameric ligand‐gated ion channel (pLGIC) family. It differs both structurally and functionally from the other six classes of 5‐HT receptors, which are G‐protein coupled receptors. 5‐HT3 receptors are pentamers, and five different subunits have been identified (5‐HT3A–E). These are widely distributed, both in the nervous system and in other tissues, although the stoichiometry of most functional heteromeric receptors is still not known. 5‐HT3 receptor activation opens a nonselective cation channel, causing depolarisation in postsynaptic cells; receptor function can be modulated by a wide range of compounds including anaesthetics, opioids and alcohols. 5‐HT3 receptors play a major role in the vomiting reflex, regulate gut motility, secretion and peristalsis in the enteric nervous system, and are involved in information transfer in the gastrointestinal tract. Disturbances within the 5‐HT3 receptor system may contribute to the pathogenesis of a range of neurological, gastrointestinal and immunological disorders.

Key Concepts

  • 5‐HT3 receptors are members of the pentameric ligand‐gated ion channel family of neurotransmitter receptors.
  • 5‐HT3 receptors have a bullet‐shaped structure, with extracellular, transmembrane and intracellular domains.
  • 5‐HT3 receptor activation opens a cation channel resulting in cell depolarisation.
  • 5‐HT3 receptor function can be modulated by a wide range of compounds including anaesthetics, opioids and alcohols.
  • 5‐HT3 receptors are involved in the function of both the central and peripheral nervous systems, including specific roles in the vomiting reflex and in the gastrointestinal tract.
  • Disturbances within the 5‐HT3 receptor system may contribute to the pathogenesis of a range of neurological, gastrointestinal and immunological disorders.
  • 5‐HT3 receptor antagonists are effective at treating nausea, emesis and irritable bowel syndrome, and have potential in a range of other disorders.

Keywords: serotonin; ligand‐gated ion channel; neurotransmitter receptor; Cys‐loop; pentamer

Figure 1. The 5‐HT3 receptor. (a): Image of the 5‐HT3A receptor (from 4PIR) showing the five subunits and the locations of the extracellular domain (ECD) transmembrane domain (TMD), which is in the lipid bilayer, and the intracellular domain (ICD), which is not complete in this image. (b): Enlarged image showing the orthosteric (agonist) binding site, which is located between two adjacent subunits in the ECD, and is rich in aromatic amino acids. (c): The orientation of 5‐HT and granisetron have been revealed in 5‐HTBP, a version of AChBP whose binding site has been modified to resemble that in the 5‐HT3 receptor. Black = 5‐HTBP residues, red = the equivalent residues in the 5‐HT3A subunit. Reprinted from Kesters et al. with permission from EMBO J.
Figure 2. Diversity in the 5‐HT3 receptor family. There are five 5‐HT3 receptor subunits in humans, and receptor heterogeneity may be achieved at many levels. Differential expression could be because of differences in transcription and/or translation (e.g. because of different promoters), while different splice variants and mutations (e.g. at places marked with stars) will yield subunits with different properties. There is also potential variation in the level of posttranslational modifications such as glycosylation and phosphorylation, and in the combinations of subunits that form functional receptors, which is currently poorly understood.
Figure 3. Schematic representation of binding sites in the 5‐HT3 receptor. Only two of the five subunits are shown. The expanded orthosteric binding site illustrates that six regions of the protein (loops A–F) contribute to agonist binding. The sites of all modulatory compounds have not yet been fully defined, but there are known examples that bind in the extracellular or the transmembrane domain.
Figure 4. The roles of 5‐HT3 receptors in diseases. Disturbances of 5‐HT3 receptors in the forebrain are relevant in neuropsychiatric disorders such as depression, schizophrenia and autism. 5‐HT3 receptors in the brain stem and dorsal root ganglia, activated by 5‐HT released after visceral stimuli, can trigger nausea and vomiting, and antagonists are especially potent against chemotherapy‐induced nausea and vomiting (CINV), radiotherapy‐induced nausea and vomiting (RINV), and postoperative nausea and vomiting. In addition, 5‐HT released in the gut stimulates 5‐HT3 receptors in the gastrointestinal (GI) tract, and their malfunction is involved in functional GI disorders such as irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD) as well as eating disorders. 5‐HT3 receptor subunits implicated in the disorders are shown in red.


Artigas F (2013) Future directions for serotonin and antidepressants. ACS Chem Neurosci. 4 (1): 5–8.

Barnes NM, Hales TG, Lummis SC and Peters JA (2009) The 5‐HT3 receptor–the relationship between structure and function. Neuropharmacology 56: 273–284.

Bétry C, Overstreet D, Haddjeri N, et al. (2015) A 5‐HT3 receptor antagonist potentiates the behavioural, neurochemical and electrophysiological actions of an SSRI antidepressant. Pharmacology, Biochemistry, and Behavior 131: 136–142.

Bhattacharya A, Dang H, Zhu QM, et al. (2004) Uropathic observations in mice expressing a constitutively active point mutation in the 5‐HT3A receptor subunit. Journal of Neuroscience 24: 5537–5548.

Brady CA, Stanford IM, Ali I, et al. (2001) Pharmacological comparison of human homomeric 5‐HT3A receptors versus heteromeric 5‐HT3A/3B receptors. Neuropharmacology 41: 282–284.

Butler AS, Lindesay SA, Dover TJ, et al. (2009) Importance of the C‐terminus of the human 5‐HT3A receptor subunit. Neuropharmacology 56 (1): 292–302.

Chen L, Ilham SJ and Feng B (2017) Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesthesiology and Pain Medicine 7 (2): e42747.

Dang H, England PM, Farivar SS, Dougherty DA and Lester HA (2000) Probing the role of a conserved M1 proline residue in 5‐hydroxytryptamine(3) receptor gating. Molecular Pharmacology 57: 1114–1122.

Davies PA, Pistis M, Hanna MC, et al. (1999) The 5‐HT3B subunit is a major determinant of serotonin‐receptor function. Nature 397: 359–363.

Davies PA (2011) Allosteric modulation of the 5‐HT3 receptor. Current Opinion in Pharmacology 11: 75–80.

Donatsch P, Engel G, Richardson BP and Stadler PA (1985) ICS 205‐930: a highly selective and potent antagonist at peripheral neuronal 5‐hydroxytryptamine (5‐HT) receptors. British Journal of Pharmacology 81, 34P.

Dubin AE, Huvar R, D'Andrea MR, et al. (1999) The pharmacological and functional characteristics of the serotonin 5‐HT(3A) receptor are specifically modified by a 5‐HT(3B) receptor subunit. Journal of Biological Chemistry 274: 30799–30810.

Eguchi J, Inomata Y, Yuasa T, Egawa M and Saito K (1997) Pharmacological profileof the novel antidepressant4‐(2‐fluorophenyl)‐6‐methyl‐2‐(1‐piperazinyl)thieno‐[2,3‐d]pyrimidinemonohydrate hydrochloride. Arzneimittel‐Forschung 47: 1337–1347.

Fiebich BL, Akundi RS, Seidel M, et al. (2004) Expression of 5‐HT3A receptors in cells of the immune system. Scandinavian Journal of Rheumatology. Supplement 119: 9–11.

Fozard JR (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5‐hydroxytryptamine receptors. Naunyn‐Schmiedeberg's Archives of Pharmacology 326: 36–44.

Gaddum JH and Picarelli ZP (1957) Two kinds of tryptamine receptor. British Journal of Pharmacology and Chemotherapy 12: 323–328.

Galligan JJ (2002) Ligand‐gated ion channels in the enteric nervous system. Neurogastroenterology and Motility 14: 611–623.

Goyal R, Salahudeen AA and Jansen M (2011) Engineering a prokaryotic Cys‐loop receptor with a third functional domain. Journal of Biological Chemistry 286: 34635–34642.

Gunthorpe MJ and Lummis SC (1999) Diltiazem causes open channel block of recombinant 5‐HT3 receptors. Journal of Physiology 519 (Pt 3): 713–722.

Gupta D, Radhakrishnan M and Kurhe Y (2015) Effect of a novel 5‐HT3 receptor antagonist 4i, in corticosterone‐induced depression‐like behavior and oxidative stress in mice. Steroids 96: 95–102.

Gupta D, Prabhakar V and Radhakrishnan M (2016) 5HT3 receptors: target for new antidepressant drugs. Neuroscience & Biobehavioral Reviews 64: 311–325.

Hammer C, Cichon S, Muhleisen TW, et al. (2012) Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: a European multicenter study. Translational Psychiatry 2: e103.

Hassaine G, Deluz C, Grasso L, et al. (2014) X‐ray structure of the mouse serotonin 5‐HT3 receptor. Nature 512 (7514): 276–281.

Holbrook JD, Gill CH, Zebda N, et al. (2009) Characterisation of 5‐HT3C, 5‐HT3D and 5‐HT3E receptor subunits: evolution, distribution and function. Journal of Neurochemistry 108: 384–396.

Jackson MB and Yakel JL (1995) The 5‐HT3 receptor channel. Annual Review of Physiology 57: 447–468.

Jansen M, Bali M and Akabas MH (2008) Modular design of Cys‐loop ligand‐gated ion channels: functional 5‐HT3 and GABA rho1 receptors lacking the large cytoplasmic M3M4 loop. Journal of General Physiology 131: 137–146.

Kapeller J, Houghton LA, Monnikes H, et al. (2008) First evidence for an association of a functional variant in the microRNA‐510 target site of the serotonin receptor‐type 3E gene with diarrhea predominant irritable bowel syndrome. Human Molecular Genetics 17: 2967–2977.

Kapeller J, Moller D, Lasitschka F, et al. (2011) Serotonin receptor diversity in the human colon: expression of serotonin type 3 receptor subunits 5‐HT3C, 5‐HT3D, and 5‐HT3E. Journal of Comparative Neurology 519: 420–432.

Kesters D, Thompson AD, Brams M, et al. (2012) Structural basis of ligand recognition in 5‐HT3 receptors. EMBO Journal 14: 49–56.

Kilpatrick GJ, Butler A, Burridge J and Oxford AW (1990) 1‐(m‐chlorophenyl)‐biguanide, a potent high affinity 5‐HT3 receptor agonist. European Journal of Pharmacology 182: 193–197.

Krzywkowski K (2006) Do polymorphisms in the human 5‐HT3 genes contribute to pathological phenotypes? Biochemical Society Transactions 34: 872–876.

Krzywkowski K, Davies PA, Feinberg‐Zadek PL, Brauner‐Osborne H and Jensen AA (2008) High‐frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5‐HT3AB receptor. Proceedings of the National Academy of Sciences of the United States of America 105: 722–727.

Lacy BE (2016) Diagnosis and treatment of diarrhea‐predominant irritable bowel syndrome. International Journal of General Medicine 9: 7–17.

Lummis SCR (2012) 5‐HT3 receptors. Journal of Biological Chemistry 287 (48): 40239–40245.

Machu TK (2011) Therapeutics of 5‐HT3 receptor antagonists: current uses and future directions. Pharmacology & Therapeutics 130: 338–347.

Morales M, Wang SD, Diaz‐Ruiz O and Jho DH (2004) Cannabinoid CB1 receptor and serotonin 3 receptor subunit A (5‐HT3A) are co‐expressed in GABA neurons in the rat telencephalon. Journal of Comparative Neurology 468: 205–216.

Niesler B, Frank B, Kapeller J and Rappold GA (2003) Cloning, physical mapping and expression analysis of the human 5‐HT3 serotonin receptor‐like genes HTR3C, HTR3D and HTR3E. Gene 310: 101–111.

Niesler B, Walstab J, Combrink S, et al. (2007) Characterization of the novel human serotonin receptor subunits 5‐HT3C,5‐HT3D, and 5‐HT3E. Molecular Pharmacology 72: 8–17.

Niesler B, Kapeller J, Hammer C and Rappold G (2008) Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 9: 501–504.

Pratt GD, Bowery NG, Kilpatrick GJ, et al. (1990) Consensus meeting agrees distribution of 5‐HT3 receptors in mammalian hindbrain. Trends in Pharmacological Sciences 11: 135–137.

Price KL, Hirayama Y and Lummis SCR (2017) Subtle differences among 5‐HT3AC, 5‐HT3AD, and 5‐HT3AE receptors are revealed by partial agonists. ACS Chemical Neuroscience 8 (5): 1085–1091.

Reeves DC and Lummis SC (2002) The molecular basis of the structure and function of the 5‐HT3 receptor: a model ligand‐gated ion channel (review). Molecular Membrane Biology 19: 11–26.

Thompson AJ and Lummis SC (2006) 5‐HT3 receptors. Current Pharmaceutical Design 12: 3615–3630.

Thompson AJ and Lummis SC (2007) The 5‐HT3 receptor as a therapeutic target. Expert Opinion on Therapeutic Targets 11: 527–540.

Thompson AJ, Lester HA and Lummis SC (2010) The structural basis of function in Cys‐loop receptors. Quarterly Reviews of Biophysics 43: 449–499.

Thompson AJ, Duke RK and Lummis SC (2011) Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5‐HT3 receptor. Molecular Pharmacology 80: 183–190.

Trattnig SM, Harpsoe K, Thygesen SB, et al. (2012) Discovery of a novel allosteric modulator of 5‐HT3 receptors: inhibition and potentiation of Cys‐loop receptor signalling through a conserved transmembrane intersubunit site. Journal of Biological Chemistry 287: 25241–25254.

Tzvetkov MV, Meineke C, Oetjen E, Hirsch‐Ernst K and Brockmoller J (2007) Tissue‐specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine. Gene 386: 52–62.

Walstab J, Rappold G and Niesler B (2010) 5‐HT3 receptors: role in disease and target of drugs. Pharmacology & Therapeutics 128: 146–169.

Yamada K, Hattori E, Iwayama Y, et al. (2006) Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biological Psychiatry 60: 192–201.

Further Reading

Bouzat C (2012) New insights into the structural bases of activation of Cys‐loop receptors. Journal of Physiology, Paris 106 (1‐2): 23–33.

Lummis SC (2015) 5‐HT3 receptors. In: Zheng J and Trudeau M (eds) Handbook of Ion Channels, pp. 331–344. Florida, USA: CRC Press.

Miller PS and Smart TG (2010) Binding, activation and modulation of Cys‐loop receptors. Trends in Pharmacological Sciences 31 (4): 161–174.

Nemecz Á, Prevost MS, Menny A and Corringer PJ (2016) Emerging molecular mechanisms of signal transduction in pentameric ligand‐gated ion channels. Neuron 90 (3): 452–470.

Nys M, Kesters D and Ulens C (2013) Structural insights into Cys‐loop receptor function and ligand recognition. Biochemical Pharmacology 86 (8): 1042–1053.

Peters JA, Hales TG and Lambert JJ (2005) Molecular determinants of single‐channel conductance and ion selectivity in the Cys‐loop family: insights from the 5‐HT3 receptor. Trends in Pharmacological Sciences 26: 587–594.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Lummis, Sarah(Jan 2018) 5‐HT3 Receptors. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0027709]